Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

LEGACY HEALTHCARE

LEGACY HEALTHCARE_logo
31
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Our drug candidate, Coacillium, is in Ph II/III for the treatment of Pediatric Alopecia Areata (AA), a debilitating autoimmune and inflammatory condition with intense psychological impact. Market potential in AA represents $2-3bn.

Epalinges, Vaud, Switzerland

Send a message

Anglais

LEGACY HEALTHCARE

Anglais

Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile population, e.g. children, cancer patients and the elderly, who may be already on multiple medications.
Our first drug, Coacillium, is currently in Phase II/III testing for the treatment of Alopecia Areata, a debilitating scalp condition with intense medical and psychological impact on all patients, especially in children, and their...

See more

Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile population, e.g. children, cancer patients and the elderly, who may be already on multiple medications.
Our first drug, Coacillium, is currently in Phase II/III testing for the treatment of Alopecia Areata, a debilitating scalp condition with intense medical and psychological impact on all patients, especially in children, and their families.
Coacillium’s safety profile is without equal. For this reason health authorities have taken the unusual step of authorizing testing in children (starting at age 2) before adult testing. We expect Coacillium to be approved by 2023 (EMA) and by 2024 (FDA), as the 1st drug for Pediatric Alopecia Areata.

Alopecia areata (AA) is a chronic autoimmune condition that causes random hair loss, up to full baldness. It affects 4.2M children globally and imposes immense psychological burden and exclusion: 66% of patients have depression and 13% are at risk of suicide.

Pediatric AA represents a €0.8B market opportunity, where no competing drugs approved for AA exist. Subsequently, Coacillium will be extended to the Adult AA market, a €2B market. Legacy is an established player in the hair disorders field and aims at launching Coacillium by itself in EU5, US & Japan, and license it elsewhere. Funds from the EIC will allow Coacillium to reach the market and restore the lives of millions of people.

  • 1

    Followers

  • 1

    Like

Our latest news

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not receive funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1478 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2667 Members
Access2EIC – Seal of Excellence
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
2140 Members
Bpifrance
Exclusive to Bpifrance clients and partners, this community aims to support and strengthen ties between these French companies in development.
2366 Members

Our history

Start in 2007

  • 2007

    Patient Safety First. Drugs made from new chemical or biological entities come with side effects.

  • 2008

    Filing of 1st patent for Coacillium and its use against hair loss of any form.

  • 2012

    Start distribution agreements via non-prescription BU's of pharma co's (Sanofi, Abbott, Galderma)

  • 2017

    Start of Phase 2/3 Raainbow study (Pediatric Alopecia Areata)

  • 2019

    Last external investor joining (former P&G vice-chairman), Eur 4.5m.

to be continued ...